Immunomedics Inc(IMMU)stock report

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.

Market Cap:4000M; Shares Outstanding:212.4M; Short Interest: 13.06%; Q3 2019(9/30/19): Cash 369M. Loss 95M

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -0.84 / -32.26%
2019.3.31 -0.46 -119.05% 45.24%
2019.6.30 -0.85 6.59% 7.00%
2019.9.30 -1.34 -8.06% -57.65%



Insider Transactions:

Institution Ownership:

Total institutions: 238,no change
Shares hold: 162000k shares. no change
shares% hold: 84.01%,no change

Analyst Ratings:

2020.01.20:7 Blockbuster Drugs Expected To Be Launched In 2020
$IMMU initiated with a Buy at BofA/Merrill $26 price target. The company recently refiled its Biologic License Application for sacituzumab govitecan after addressing manufacturing issues, and the FDA’s potential acceptance in January is a “key catalyst”

Leave a Reply